Clinical Research Directory

Inclusion Criteria: Patients may be included in the study only if they meet all of the following criteria: * Age ≥ 21 years. * Histological or cytological diagnosis solid organ malignancy * Available results of comprehensive NGS panel testing performed on either tumour tissue or blood-based assay. If results are from blood-based assay, test must have been performed in the metastatic setting. * ECOG 0-2. * At least 1 measurable tumour lesions based on RECIST 1.1 criteria * Estimated life expectancy of at least 12 weeks. * Has documented progressive disease from last line of therapy. * Has received at least 2 lines of palliative systemic therapy with no available standard therapy: * Adequate organ function including the following: * Bone marrow: * Absolute neutrophil (segmented and bands) count (ANC) ≥ 1.5 x 109/L * Platelets ≥ 100 x 109/L * Haemoglobin ≥ 8 x 109/L * Hepatic: * Bilirubin ≤ 1.5 x upper limit of normal (ULN), * ALT or AST ≤ 2.5x ULN, (or ≤ 5 X with liver metastases) * Renal: * Creatinine ≤ 1.5x ULN * Signed informed consent from patient or legal representative. * Able to comply with study-related procedures. Exclusion Criteria: * Treatment within the last 30 days with any investigational drug. * Concurrent administration of any other tumour therapy, including cytotoxic chemotherapy, hormonal therapy, and immunotherapy. * Major surgery within 28 days of study drug administration. * Active infection that in the opinion of the investigator would compromise the patient's ability to tolerate therapy. * Pregnancy. * Breast feeding. * Serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator. * Active bleeding disorder or bleeding site. * Non-healing wound. * Second primary malignancy that is clinically detectable at the time of consideration for study enrolment. * Symptomatic brain metastasis.